Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Robert Morgan, MS, JD
Sponsor GmbH
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Yale Cancer Center
New Haven, Connecticut, United States
- Ochsner Clinic Foundation
New Orleans, Louisiana, United States
- University of Michigan
Ann Arbor, Michigan, United States
- Karmanos Cancer Institute
Detroit, Michigan, United States
- University of Nebraska Medical Center
Omaha, Nebraska, United States
- Duke University Medical Center
Durham, North Carolina, United States
- Cleveland Clinic - Taussig Cancer Institute
Cleveland, Ohio, United States
- Abramson Cancer Center - University of Pennsylvania
Philadelphia, Pennsylvania, United States
- Md Anderson Cancer Center
Houston, Texas, United States
- Mays Cancer Center Ut Health San Antonio
San Antonio, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 24 May 2018
- Primary completion
- 17 Oct 2019
- Completion
- 10 Mar 2020
- Last update posted
- 15 Nov 2022
- Registered enrollment
- 4
- Registry id
- NCT03373877
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.